Literature DB >> 2323510

The carbohydrate composition of mucin in colonic cancer.

C R Boland1, G D Deshmukh.   

Abstract

Mucins synthesized in colonic cancer are known to be different from those in the normal colon; however, the biochemical differences between these mucins have not been defined. We have purified mucins from samples of nonneoplastic (normal) human colon and colon cancer and found that the carbohydrate content of the cancer-associated mucins is 48% of that in the normal colon, including significant reductions in galactose, N-acetylglucosamine, N-acetylgalactosamine, and fucose. By subjecting the mucins to alkaline degradation, we determined that there are 19% fewer oligosaccharide chains per milligram of cancer-associated colonic mucin than there are in mucins from normal colons. We also found a reduction in mean oligosaccharide chain length in cancer-associated mucin (5.83 carbohydrate residues per chain) compared with those derived from normal colons (10.2 residues). Total and individual amino acid contents were greater in cancer-associated mucins, with the exception of three amino acids (threonine, serine, and proline), two of which represent the O-linked glycosylation sites for glycoproteins. Thus, mucins are aberrantly glycosylated in colon cancer, both in terms of the number and mean chain length of the oligosaccharide moiety. Because of their relative abundance in colonic tissue, mucins appear to be useful molecular species in the study of the derangements in protein glycosylation that occur during neoplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323510     DOI: 10.1016/0016-5085(90)90330-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence.

Authors:  A P Corfield; N Myerscough; B F Warren; P Durdey; C Paraskeva; R Schauer
Journal:  Glycoconj J       Date:  1999-06       Impact factor: 2.916

2.  Clement Richard Boland, Jr., MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Clement Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 3.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

4.  Characterization of mucin in whole-gut lavage fluid obtained from patients with inflammatory bowel disease.

Authors:  H Saitoh; K Takagaki; T Nakamura; A Munakata; Y Yoshida; M Endo
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

5.  Diagnostic value of DNA image cytometry in ulcerative colitis.

Authors:  R Keller; E C Foerster; A Köhler; B Floer; G Winde; H J Terpe; W Domschke
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

Review 6.  Altered glycosylation in inflammatory bowel disease: a possible role in cancer development.

Authors:  B J Campbell; L G Yu; J M Rhodes
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

7.  Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.

Authors:  B J Campbell; I A Finnie; E F Hounsell; J M Rhodes
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis.

Authors:  R S Bresalier; Y Niv; J C Byrd; Q Y Duh; N W Toribara; R W Rockwell; R Dahiya; Y S Kim
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

Authors:  Kristiaan Lenos; Jeroen A C M Goos; Ilona M Vuist; Sjoerd H den Uil; Pien M Delis-van Diemen; Eric J Th Belt; Hein B A C Stockmann; Herman Bril; Meike de Wit; Beatriz Carvalho; Susan Giblett; Catrin A Pritchard; Gerrit A Meijer; Yvette van Kooyk; Remond J A Fijneman; Sandra J van Vliet
Journal:  Oncotarget       Date:  2015-09-22

10.  Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.

Authors:  V Apostolopoulos; P X Xing; J A Trapani; I F McKenzie
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.